Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
-
Bristol-Myers Squibb (NYSE:BMY) plans to present extensive new clinical data at the 2026 ASCO Annual Meeting.
-
The company will share more than 60 scientific disclosures, including 19 oral presentations across oncology programs.
-
Late-breaking Phase 3 data, including SUCCESSOR-2 for mezigdomide and izalontamab brengitecan, will be highlighted.
-
The updates cover multiple myeloma, lymphoma, breast and lung cancers, and several emerging oncology mechanisms.
For investors tracking NYSE:BMY, this ASCO update comes with the stock at a share price of $58.03 and a value score of 4. Over the past year, the stock is up 29.9%, with a year-to-date return of 8.5%, while the 5-year return sits at 9.0%. These figures describe how the market has been treating the company as it brings new oncology data into focus.
The scale of Bristol-Myers Squibb’s upcoming disclosures provides additional information on how broad and mature its oncology pipeline has become. As the Phase 3 readouts and real-world evidence are released at ASCO, investors will be able to reassess how these programs might influence the company’s future value drivers within multiple cancer treatment areas.
Stay updated on the most important news stories for Bristol-Myers Squibb by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Bristol-Myers Squibb.
NYSE:BMY Earnings & Revenue Growth as at May 2026
We’ve flagged 3 risks for Bristol-Myers Squibb. See which could impact your investment.
Bristol-Myers Squibb’s ASCO presence signals how central oncology remains to its business model at a time when it is also facing a patent cliff on large legacy drugs. More than 60 disclosures, including late breaking Phase 3 data in multiple myeloma, lymphoma, triple negative breast cancer, esophageal cancer and lung cancer, give investors a concentrated look at how broad the oncology pipeline actually is. For a company competing with Merck, Pfizer and Johnson & Johnson, showing late stage results for targeted protein degraders, antibody drug conjugates and cell therapies is about defending and expanding its position in complex cancers where treatment standards are still evolving.
How This Fits Into The Bristol-Myers Squibb Narrative
-
The depth of ASCO data across CELMoD agents, bispecific antibodies and CAR T cell therapies supports the existing narrative that a large, late stage pipeline is one of Bristol-Myers Squibb’s key tools to address upcoming patent expiries.
-
Concentrating so much attention on oncology can challenge the narrative’s aim of broader diversification, because it keeps a heavy focus on a therapeutic area where competition and pricing pressure from peers are already intense.
-
The specific real world CAR T outcomes and first disclosures for assets such as pumitamig and izalontamab brengitecan sit on top of the current narrative, which does not yet fully reflect how real world evidence and newer modalities might affect future decision making.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Bristol-Myers Squibb to help decide what it is worth to you.
The Risks and Rewards Investors Should Consider
-
⚠️ A broad oncology pipeline still carries execution risk, because weaker than expected Phase 3 or real world results could make it harder to offset revenue pressure from expiring patents such as Eliquis and Opdivo.
-
⚠️ Running many complex trials at once increases cost and operational complexity, which can weigh on profitability if only a small subset of programs ultimately receive approvals or strong physician uptake.
-
🎁 Multiple late breaking Phase 3 readouts across different tumor types give Bristol-Myers Squibb several potential paths to refresh its oncology portfolio and keep a presence in high need cancers where competitors are also active.
-
🎁 Additional real world data around cell therapies such as Breyanzi can help refine how these products are used, which may support more efficient resource use and strengthen the case for further cell therapy investment compared with peers.
What To Watch Going Forward
From here, it is useful to watch the actual efficacy and safety profiles that emerge from the SUCCESSOR 2 multiple myeloma trial, the triple negative breast cancer and esophageal studies for izalontamab brengitecan, and the NSCLC data for pumitamig, and how oncologists react to them against existing options from Merck, Pfizer and others. Pay attention to whether management starts to highlight any of these agents as future cornerstone products, and if ASCO results trigger changes in trial priorities, partnership terms or capital allocation. Investors can also track how often real world CAR T outcomes are used to support label updates, treatment guidelines or reimbursement discussions, because that will shape the long term role of cell therapy in Bristol-Myers Squibb’s portfolio.
To ensure you are always in the loop on how the latest news impacts the investment narrative for Bristol-Myers Squibb, head to the community page for Bristol-Myers Squibb to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BMY.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com